CoChat

mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants

Open access
Chaki, Shigeyuki, Ago, Yukio, Palucha-Paniewiera, Agnieszka, Matrisciano, Francesco, Pilc, Andrzej · 2013 · Neuropharmacology
Cited by 116

The DOI matches its Crossref record; 40 of the 40 references it cites were found in a registry or an index.

Abstract

Major depressive disorder is among the most prevalent forms of mental illness. All currently available antidepressant medications have stemmed from study of the mechanisms of serendipitously discovered drugs, and only 30-50% of patients exhibit remission and frequently at least 3-4 weeks are required for manifestation of significant therapeutic effects. To overcome these drawbacks, discovering novel neuronal mechanisms of pathophysiology of depression as well as more effective treatments are necessary. This review focuses on the metabotropic glutamate (mGlu) receptors and their potential for drug targets for the treatment of depression. In particular, accumulating evidence has indicated the potential importance and usefulness of agents acting on mGlu2/3 and mGlu5 receptors. Preclinical and clinical evidence of mGlu2/3 receptor ligands and mGlu5 receptor antagonists are described. Moreover, their potential in clinic will be discussed in the context of neuronal mechanisms of ketamine, an agent recently demonstrated a robust effect for patients with treatment-resistant depression. This article is part of a Special Issue entitled 'Metabotropic Glutamate Receptors'.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/j.neuropharm.2012.05.022

Cites

40 of 40 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 40 references

Cited by

See all 116

Metadata

Authors
Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., & Pilc, A.
Venue
Neuropharmacology
Publisher
Elsevier BV
Published
2013-03
Volume
66
Pages
40-52
ISSN
0028-3908 (ISSN-L)
OpenAlex
W2012827629
Cited by
116
References
40
FWCI
9.91
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. https://app.cochat.ai/papers/10.1016/j.neuropharm.2012.05.022
The paper
Chaki, S., Ago, Y., Palucha-Paniewiera, A., Matrisciano, F., & Pilc, A. (2013). mGlu2/3 and mGlu5 receptors: Potential targets for novel antidepressants. Neuropharmacology. https://doi.org/10.1016/j.neuropharm.2012.05.022

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.